Innovus Pharma Signs Exclusive License and Distribution Agreement
with Luminarie in Australia, New Zealand and the Philippines for Zestra®
for Female Sexual Arousal Disorder and Zestra Glide® for Female
Lubrication

May 22, 2017 06:05 AM Eastern Daylight Time

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB
Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases, announced
today the signing of an exclusive license and distribution agreement
with Luminarie Pty Ltd (“Luminarie”), a company based in Australia for
the commercialization of Zestra® and Zestra Glide® in Australia, New
Zealand and the Philippines.

“Part of our plan to increase revenues from our international
distributors is to expand into the Asia-Pacific region,” said Innovus
Pharma CEO Dr. Bassam Damaj. “We are very happy to be teaming-up with
Luminarie in Australia, New Zealand and the Philippines to market our
Zestra® and Zestra Glide® products. Luminaire is now our 16th
distribution partner for our products outside the United States and we
look forward to expanding our sales into these important countries with
them,” continued Dr. Damaj.

“We are delighted to be working with Innovus Pharma on the
commercialization of their Zestra® and Zestra Glide® products into
Australia, New Zealand and the Philippines,” said Hemant Gulhane, CEO of
Luminarie. “We love the fact that these products represent a well-known
brand with extensive clinical trials. We believe each product will be
well received in these countries and will meet a large unmet patient
need.”

About Zestra®

Zestra® is currently exclusively partnered with Orimed Pharma, the OTC
subsidiary of Jamp Pharma in Canada, Densmore Pharmaceutical
International in France and Belgium, DanaLife ApS in select European
markets, Sothema Laboratories for the Middle East and North Africa, Elis
Pharmaceuticals in Turkey and certain select markets, Oz Biogenics for
Myanmar and Vietnam, BioTask in Malaysia and J&H Co. LTD in South Korea,
and non-exclusively to PT Resources in Hong Kong and certain select
Asian markets.

Zestra® is approved in Canada, the 28 countries of the European Union,
India, Hong Kong, the United Arab Emirates (“UAE”), United Kingdom and
Morocco. Innovus currently generates revenues from the following markets
for Zestra®: Canada, Morocco, South Korea, certain European countries
and Hong Kong in addition to the United States as its biggest market.

About Zestra® and FSI/AD

Zestra® is a patented blend of natural oils clinically proven in
double-blind placebo-controlled clinical trials in 276 women to increase
in a statistical significant manner the arousal, desire and sexual
satisfaction in FSI/AD women. To the Company’s knowledge, Zestra® is the
first NHP product to receive approval for the indication of FSI/AD in
Canada. To date, no product has been approved to treat FSI/AD, a
persistent or recurring inability to attain or maintain adequate sexual
excitement until the completion of a sexual activity. The diagnosis can
also refer to an inadequate lubrication-swelling response normally
present during arousal and sexual activity causing personal distress.
Published papers on the FSI/AD market size estimate it to be equal or
larger than the market for erectile dysfunction in males, and possibly
larger.

Approximately 43% of women in the United States age 18 to 59, or ~50
million, experience some form of Female Sexual Dysfunction (“FSD”)
according to a published study. (Laumann, E.O. et al. Sexual Dysfunction
in the United States: Prevalence and Predictors. JAMA, Feb. 10, 1999.
vol. 281, No. 6.537-542) and (http://www.indexmundi.com/south_korea/demographics_profile.html).
The FSD market in the United States is estimated to be more than $1
billion per year. For more information on Zestra®, please visit www.zestra.com.

About Zestra Glide®

Zestra Glide® is currently exclusively partnered with Orimed Pharma in
Canada, Sothema Labs in the Middle East and North Africa, Elis Pharma in
Turkey and certain select markets, Oz Biogenics in Myanmar and Vietnam,
and KLabs in India.

Zestra Glide® is currently approved in 32 countries and marketed and
sold in three countries, including the United States, Canada and
Morocco. For more information on Zestra Glide®, please visit www.zestra.com/glide.

About Zestra Glide® and the Lubricant Market

Zestra Glide® is the only water-based clinically tested lubricant with
high viscosity. Increased viscosity usually translates into longer
effects. The lubricant market is estimated to be around $200 million in
the U.S. (Symphony IRI Group Study, 2012).

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging
over-the-counter (“OTC”) consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development of
safe and effective non-prescription medicine and consumer care products
to improve men’s and women’s health and vitality and respiratory
diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and
health products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and therapists, and
(c) directly to consumers through our on-line channels, retailers and
wholesalers. The Company is dedicated to being a leader in developing
and marketing new OTC and branded Abbreviated New Drug Application
(“ANDA”) products. The Company is actively pursuing opportunities where
existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC.

Luminarie is an innovative healthcare company, operating in Australia,
New Zealand, the Philippines, China and Canada, bringing to market new
unique products within the consumer healthcare and pharmaceutical space.
With an experienced team of pharmaceutical industry professionals,
Luminaire is building a portfolio of brands that consumers will come to
recognize and love.

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, to successfully
commercialize Zestra®, Zestra Glide® and other products in Australia,
New Zealand and the Philippines and in other countries in the European
Union, the U.S. and internationally and to achieve its other
development, commercialization, financial and staffing objectives.
Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company's most recent filing
on Form S-1, annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC's website or without charge from the
Company.